Data | Hora | Fonte | Título | Código | Companhia |
05/05/2010 | 17:00 | Business Wire | Allos Therapeutics Reports First Quarter 2010 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
04/05/2010 | 16:22 | Edgar (US Regulatory) | Confidential Treatment Order (CT ORDER) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
30/04/2010 | 07:06 | Edgar (US Regulatory) | Proxy Statement (definitive) (DEF 14A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
28/04/2010 | 18:40 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
27/04/2010 | 18:01 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
27/04/2010 | 09:00 | Business Wire | Allos Therapeutics Appoints Dr. Charles Morris as Chief Medical Officer | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
21/04/2010 | 09:00 | Business Wire | Allos Therapeutics to Report First Quarter 2010 Financial Results on May 5, 2010 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
14/04/2010 | 18:07 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
09/04/2010 | 17:34 | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting (preliminary) (PRE 14A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
10/03/2010 | 18:20 | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
01/03/2010 | 18:46 | Edgar (US Regulatory) | Annual Report (10-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
01/03/2010 | 18:00 | Business Wire | Allos Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
24/02/2010 | 11:01 | Business Wire | Allos Therapeutics to Participate in RBC Capital Markets Health Care Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
17/02/2010 | 11:00 | Business Wire | Allos Therapeutics to Report Fourth Quarter and Full Year 2009 Results on March 1, 2010 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
16/02/2010 | 20:35 | Edgar (US Regulatory) | Annual Statement of Changes in Beneficial Ownership (5) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
16/02/2010 | 15:48 | Edgar (US Regulatory) | Statement of Ownership (SC 13G) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
10/02/2010 | 16:25 | PR Newswire (US) | MedNet Solutions Deploys Global Peripheral T-cell Lymphoma Registry for Allos Therapeutics | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
03/02/2010 | 11:00 | Business Wire | Allos Therapeutics to Present at BIO CEO & Investor Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
06/01/2010 | 11:00 | Business Wire | Allos Therapeutics to Present at J.P. Morgan Healthcare Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
11/12/2009 | 09:25 | Marketwired | Wall St Sense Offers In-depth Research on the Services, Financial and Healthcare Sectors' Key Players | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
08/12/2009 | 12:15 | Business Wire | Allos Therapeutics’ FOLOTYN™ Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Ly... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
07/12/2009 | 16:22 | Dow Jones News | 2nd UPDATE: Celgene To Buy Gloucester Pharma for At Least $340 Million | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
07/12/2009 | 13:00 | Business Wire | Allos Therapeutics’ FOLOTYN™ Demonstrates Activity in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Tre... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/12/2009 | 13:00 | Business Wire | Allos Therapeutics Reports New Analyses of Data from Pivotal PROPEL Trial of FOLOTYN™ at 51st ASH Annual Meeting | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
04/12/2009 | 11:00 | Business Wire | Allos Therapeutics Announces an Agreement with Idis for a Named Patient Program for FOLOTYN™ (pralatrexate injection) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
03/12/2009 | 11:00 | Business Wire | Allos Therapeutics to Launch Global Registry for Patients with Peripheral T-Cell Lymphoma at the American Society of Hematolo... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
30/11/2009 | 11:00 | Business Wire | Allos Therapeutics Announces Issuance of U.S. Patent for FOLOTYN | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
23/11/2009 | 09:38 | Marketwired | Ridgewater Equity Reviews the Following Equities Human Genome Sciences Inc., Intuit Inc., Advanced Battery Technologies, Linn En | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
11/11/2009 | 11:00 | Business Wire | Allos Therapeutics Announces New Data on FOLOTYN™ to be Presented at the American Society of Hematology Meeting | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
11/11/2009 | 09:54 | Marketwired | AnalystChoice.com Provides Analytical Coverage on ELNK, NWSA, NTAP, ALTH, HANS and BPOP | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |